IntelliPharmaCeutics International (IntelliPharmaCeutics International) Revenue per Share : $0.03 (TTM As of Aug. 2023)

View and export this data going back to 1996. Start your Free Trial

What is IntelliPharmaCeutics International Revenue per Share?

IntelliPharmaCeutics International's revenue per share for the three months ended in Aug. 2023 was $0.00. IntelliPharmaCeutics International's revenue per share for the trailing twelve months (TTM) ended in Aug. 2023 was $0.03.

Warning Sign:

IntelliPharmaCeutics International Inc revenue per share has been in decline over the past 3 years.

During the past 12 months, the average Revenue Per Share Growth Rate of IntelliPharmaCeutics International was 825.00% per year. During the past 3 years, the average Revenue Per Share Growth Rate was -75.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for IntelliPharmaCeutics International's Revenue per Share or its related term are showing as below:

IPCIF' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -81.2 Med: -30.05 Max: 232.9
Current: -75.9

During the past 13 years, IntelliPharmaCeutics International's highest 3-Year average Revenue Per Share Growth Rate was 232.90% per year. The lowest was -81.20% per year. And the median was -30.05% per year.

IPCIF's 3-Year Revenue Growth Rate is ranked worse than
97.93% of 773 companies
in the Biotechnology industry
Industry Median: 5.5 vs IPCIF: -75.90

IntelliPharmaCeutics International Revenue per Share Historical Data

The historical data trend for IntelliPharmaCeutics International's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IntelliPharmaCeutics International Revenue per Share Chart

IntelliPharmaCeutics International Annual Data

Trend

Nov13

Nov14

Nov15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

Revenue per Share

Get a 7-Day Free Trial

0.36

0.16

0.06

IntelliPharmaCeutics International Quarterly Data
	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23
Revenue per Share	Get a 7-Day Free Trial															-	-	0.01	0.02	-

Competitive Comparison of IntelliPharmaCeutics International's Revenue per Share

For the Biotechnology subindustry, IntelliPharmaCeutics International's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IntelliPharmaCeutics International's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IntelliPharmaCeutics International's PS Ratio distribution charts can be found below:

* The bar in red indicates where IntelliPharmaCeutics International's PS Ratio falls into.

IntelliPharmaCeutics International Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

IntelliPharmaCeutics International's Revenue Per Share for the fiscal year that ended in Nov. 2022 is calculated as

Revenue Per Share (A: Nov. 2022 )	=	Revenue (A: Nov. 2022 )	/	Shares Outstanding (Diluted Average) (A: Nov. 2022 )
	=	0.066	/	33.093
	=	0.00

IntelliPharmaCeutics International's Revenue Per Share for the quarter that ended in Aug. 2023 is calculated as

Revenue Per Share (Q: Aug. 2023 )	=	Revenue (Q: Aug. 2023 )	/	Shares Outstanding (Diluted Average) (Q: Aug. 2023 )
	=	0.069	/	33.093
	=	0.00

Revenue per Share for the trailing twelve months (TTM) ended in Aug. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.03

IntelliPharmaCeutics International (OTCPK:IPCIF) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

IntelliPharmaCeutics International Revenue per Share Related Terms

Thank you for viewing the detailed overview of IntelliPharmaCeutics International's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

IntelliPharmaCeutics International (IntelliPharmaCeutics International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IntelliPharmaCeutics International Inc (OTCPK:IPCIF) » Definitions » Revenue per Share

Comparable Companies

Traded in Other Exchanges

I4AA:Germany IPCI:Canada

Address

30 Worcester Road, Toronto, ON, CAN, M9W 5X2

Website

https://www.intellipharmaceutics.com

IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, and pain. The company's product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.